FEATURED BLOGS
Jun 19, 2018
Dr. Jaime G. de la Garza-Salazar remembers his friend and mentor on what would have been Dr. Bisel's 100th birthday.
Jun 19, 2018
This was a patient who needed to do cancer her way, and making it about me was not going to work
Jun 11, 2018
As a pragmatic investigator and physician who has witnessed remarkable progress in the treatments we can now offer individuals with cancer, I believe the FDA’s support of more rapid and nimble...
Jun 08, 2018
Drs. Margaret Gatti-Mays, Kathryn Lurain, and Fatima Karzai outline how effective mentorship and social media support can help contribute to gender equity in medical leadership positions.
Jun 02, 2018
As clinicians and researchers at this pivotal time in cancer research and cancer care, we need to extensively characterize our patients’ tumors, treat them with our most effective agents, and support...
May 24, 2018
In the midst of troubles in North Africa and Middle East, we keep up with oncology education and research and keep up hope for the betterment of patient care and advancement of science in Arab...
May 24, 2018
While more biosimilars will likely be available in oncology in the next several years, their specific impact on patient care is going to depend on patient and provider acceptance of these agents.

Advertisement

Latest Comments & Discussions


ASCO University
Jun 18, 2018
Discussion Questions 1. What was the cause of the patient’s fevers, clinical symptoms after CAR T cells and biochemical abnormalities...

ASCO University
Jun 18, 2018
Patient Case Update The patient has refractory B ALL and residual disease after multiple therapies.  While options included...

Jennifer Dunlap
Jun 18, 2018
Course Faculty Response - Dr. Jennifer Dunlap Question 1 response: CAR-T cell therapy is a consideration in this patient. CAR-T cell...

David Porter
Jun 18, 2018
Course Faculty Response - Dr. David Porter Question 1 response: This patient has refractory ALL. He is incurable with standard...

Robert K. Oldham, MD
Jun 16, 2018
Not much new in these comments.  ASCO needs to be more supportive of patient access to new drugs rather than supporting the same old...

Pages

Most Read

As clinicians and researchers at this pivotal time in cancer research and cancer care, we need to extensively characterize our patients’ tumors, treat them with our most effective agents, and support a robust research effort to improve the efficacy of the drugs.
Congratulations to the recipients of the 2018 Advanced Clinical Research Award, Career Development Awards, Young Investigator Awards, Global Oncology Young Investigator Awards, and Gianni Bonadonna Breast Cancer Research Fellowship. 
FASCO is something earned through service to ASCO and to the field of oncology. One cannot apply or pay a fee to receive it.
In the midst of troubles in North Africa and Middle East, we keep up with oncology education and research and keep up hope for the betterment of patient care and advancement of science in Arab countries. 
Dr. Edward S. Kim encourages you to register today and join the Research Community Forum in September for 2 days of learning and collaboration.

Tweets from ASCO

Tweets from Oncology Community